An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)-Reference-Cited by-同舟云学术

An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)

Published:2020-04-28 Issue:2 Volume:4 Page:79-84
ISSN:2432-3853
Container-title:Journal of the Anus, Rectum and Colon
language:en
Short-container-title:J Anus Rectum Colon

Author:

Matsuoka Hiroshi¹,Ogata Yutaka²,Nakamura Michio³,Shibata Yoshihisa⁴,Munemoto Yoshinori⁵,Bando Hiroyuki⁶,Nishijima Koji⁷,Okuda Hiroyuki⁸,Terada Itsuro⁹,Shiroiwa Takeru¹⁰,Kishimoto Junji¹¹,Maeda Kotaro¹²

Affiliation:

1. Department of Surgery, Fujita Health University

2. Department of Surgery, Kurume University

3. Department of gastroenterology, Sapporo City General Hospital

4. Department of Surgery, Toyohashi Municipal Hospital

5. Department of Surgery, Fukuiken Saiseikai Hospital

6. Department of Surgery, Ishikawa Prefectural Central Hospital

7. Department of Surgery, Kanazawa Red Cross Hospital

8. Department of Clinical oncology, Keiyukai Sapporo hospital

9. Department of Surgery, Toyama City Hospital

10. Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (NIPH)

11. Clinical Research Support Center Kyushu

12. Fujita Health University Hospital International Medical center

Publisher

The Japan Society of Coloproctology

Link

https://www.jstage.jst.go.jp/article/jarc/4/2/4_2019-020/_pdf

Reference13 articles.

1. 1. Matsuoka H, Katagata Y, Ohta H, et al. A multidisciplinary approach to the management of capecitabine-associated hand foot syndrome in cancer patients receiving capecitabine plus oxaliplatin and bevacizumab for advanced colorectal cancer. Fujita Medical Journal. 2017 Feb; 3 (1): 1-5.

2. 2. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folic acid plus oxaliplatin (FOLFOX4) as second-line therapy in metastatic colorectal camcer: a randomized phase III noninferiority study. Ann Oncol. 2008 Oct; 19 (10): 1720-6.

3. 3. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folic acid plus oxaliplatin as first-line therapy for metastaic colorectal cancer. J Clin Oncol. 2008 Oct; 26 (27): 2006-12.

4. 4. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX4 as first-line therapy for metastatic colorectal cancer 16966 update results. Br J Cancer. 2011 Jun; 105 (1): 58-64.

5. 5. Sharma A, Walker LG, Monson J. Baseline quality of life factors predict long term survival after elective resection for colorectal cancer. Int J Surg Oncol. 2013 Oct; 2013: 1-6.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the impact of systemic dexamethasone dosage on docetaxel-induced hand-foot syndrome in patients with breast cancer;Scientific Reports;2024-06-18

2. Circulating miR-449a predicts survival outcome for colorectal cancer following curative resection;Medicine;2021-04-16